Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved.BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of an…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
